Does Ibuprofen Worsen COVID-19?

SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor

Hoffmann, M., Kleine-Weber, H., Schroeder, S., Krüger, N., Herrler, T., Erichsen, S., Schiergens, T. S., Herrler, G., Wu, N.-H., Nitsche, A., et al. (2020) · Cell · doi:10.1016/j.cell.2020.02.052 · Cited by 20,286 · see citing works

Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study

Yang, X., Yu, Y., Xu, J., Shu, H., Xia, J., Liu, H., Wu, Y., Zhang, L., Yu, Z., Fang, M., et al. (2020) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(20)30079-5 · Cited by 10,066 · see citing works

Receptor Recognition by the Novel Coronavirus from Wuhan: an Analysis Based on Decade-Long Structural Studies of SARS Coronavirus

Wan, Y., Shang, J., Graham, R., Baric, R. S., & Li, F. (2020) · Journal of Virology · doi:10.1128/jvi.00127-20 · Cited by 4,341 · cited 1× · see citing works

Clinical characteristics of 140 patients infected with SARS‐CoV‐2 in Wuhan, China

Zhang, J., Dong, X., Cao, Y., Yuan, Y.-D., Yang, Y., Yan, Y., Akdiş, C. A., & Gao, Y. (2020) · Allergy · doi:10.1111/all.14238 · Cited by 4,004 · see citing works

Are patients with hypertension and diabetes mellitus at increased risk for COVID-19 infection?

Fang, L., Karakiulakis, G., & Roth, M. (2020) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(20)30116-8 · Cited by 2,947 · see citing works

Renin-angiotensin-aldosterone system inhibitors in patients with Covid-19

Vaduganathan, M., Vardeny, O., Michel, T., McMurray, J. J. V., Pfeffer, M. A., & Solomon, S. D. (2020) · New England Journal of Medicine · doi:10.1056/nejmsr2005760 · Cited by 2,101 · see citing works

Renin–Angiotensin–Aldosterone System Blockers and the Risk of Covid-19

Mancia, G., Rea, F., Ludergnani, M., Apolone, G., & Corrao, G. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2006923 · Cited by 1,071 · see citing works

Renin–Angiotensin–Aldosterone System Inhibitors and Risk of Covid-19

Reynolds, H. R., Adhikari, S., Pulgarin, C., Troxel, A. B., Iturrate, E., Johnson, S. B., Hausvater, A., Newman, J. D., Berger, J. S., Bangalore, S., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2008975 · Cited by 1,058 · see citing works

Clinical Features and Treatment of COVID-19 Patients in Northeast Chongqing

Wan, S., Xiang, Y., Fang, W., Zheng, Y., Li, B., Hu, Y., Lang, C., Huang, D., Sun, Q., Xiong, Y., et al. (2020) · Journal of Medical Virology · doi:10.1002/jmv.25783 · Cited by 982 · see citing works

ecancermedicalscience

Bouche, G., André, N., Banavali, S. D., Berthold, F., Berruti, A., Bocci, G., Brandi, G., Cavallaro, U., Cinieri, S., Colleoni, M. A., et al. (2016) · ecancermedicalscience · doi:10.3332/ecancer.2014.463 · Cited by 678 · see citing works

A Comparative Study on the Clinical Features of Coronavirus 2019 (COVID-19) Pneumonia With Other Pneumonias

Zhao, D., Yao, F., Wang, L., Zheng, L., Gao, Y., Ye, J., Guo, F., Zhao, H., & Gao, R. (2020) · Clinical Infectious Diseases · doi:10.1093/cid/ciaa247 · Cited by 488 · see citing works

Associations between immune-suppressive and stimulating drugs and novel COVID-19—a systematic review of current evidence

Russell, B. A., Moss, C. L., George, G., Santaolalla, A., Cope, A. P., Papa, S., & Hemelrijck, M. V. (2020) · ecancermedicalscience · doi:10.3332/ecancer.2020.1022 · Cited by 440 · see citing works

Covid-19: ibuprofen should not be used for managing symptoms, say doctors and scientists

Day, M. J. (2020) · BMJ · doi:10.1136/bmj.m1086 · Cited by 399 · see citing works

SARS-CoV2: should inhibitors of the renin–angiotensin system be withdrawn in patients with COVID-19?

Kuster, G. M., Pfister, O., Burkard, T., Zhou, Q., Twerenbold, R., Haaf, P., Widmer, A. F., & Osswald, S. (2020) · European Heart Journal · doi:10.1093/eurheartj/ehaa235 · Cited by 395 · see citing works

COVID-19 and treatment with NSAIDs and corticosteroids: should we be limiting their use in the clinical setting?

Russell, B. A., Moss, C. L., Rigg, A. S., & Hemelrijck, M. V. (2020) · ecancermedicalscience · doi:10.3332/ecancer.2020.1023 · Cited by 286 · see citing works

Impact of Safety Alerts on Measures of Disproportionality in Spontaneous Reporting Databases

Pariente, A., Grégoire, F., Fourrier‐Réglat, A., Haramburu, F., & Moore, N. D. (2007) · Drug Safety · doi:10.2165/00002018-200730100-00007 · Cited by 270 · see citing works

Non-steroidal anti-inflammatory drugs and covid-19

Little, P. S. (2020) · BMJ · doi:10.1136/bmj.m1185 · Cited by 228 · see citing works

Liver and Kidney Injuries in COVID-19 and Their Effects on Drug Therapy; a Letter to Editor.

Rismanbaf, A., & Zarei, S. (2020) · Archives of Academic Emergency Medicine · doi:10.22037/aaem.v8i1.590 · Cited by 175 · see citing works

Invasive Group A Streptococcal Infection and Nonsteroidal Antiinflammatory Drug Use Among Children With Primary Varicella

Lesko, S. M., O’Brien, K. L., Schwartz, B., Vezina, R. M., & Mitchell, A. A. (2001) · PEDIATRICS · doi:10.1542/peds.107.5.1108 · Cited by 158 · see citing works

Ibuprofen Attenuates Cardiac Fibrosis in Streptozotocin-Induced Diabetic Rats

Qiao, W., Wang, C., Chen, B., Zhang, F., Liu, Y., Lü, Q., Guo, H., Yan, C., Sun, H. B., Hu, G., et al. (2015) · Cardiology · doi:10.1159/000375362 · Cited by 137 · see citing works

Inhibitors of the Renin–Angiotensin–Aldosterone System and Covid-19

Jarcho, J. A., Ingelfinger, J. R., Hamel, M. B., D’Agostino, R. B., & Harrington, D. P. (2020) · New England Journal of Medicine · doi:10.1056/nejme2012924 · Cited by 128 · see citing works

Risks Related to the Use of Non-Steroidal Anti-Inflammatory Drugs in Community-Acquired Pneumonia in Adult and Pediatric Patients

Voiriot, G., Philippot, Q., Elabbadi, A., Elbim, C., Chalumeau, M., & Fartoukh, M. S. (2019) · Journal of Clinical Medicine · doi:10.3390/jcm8060786 · Cited by 119 · see citing works

Transplantation for Acute Liver Failure in Patients Exposed to NSAIDs or Paracetamol (Acetaminophen)

Gülmez, S. E., Larrey, D. G., Pageaux, G., Lignot, S., Lassalle, R., Jové, J., Gatta, A., McCormick, P. A., Metselaar, H. J., Monteiro, E., et al. (2013) · Drug Safety · doi:10.1007/s40264-012-0013-7 · Cited by 108 · see citing works

Ibuprofen, paracetamol, and steam for patients with respiratory tract infections in primary care: pragmatic randomised factorial trial

Little, P. S., Moore, M. V., Kelly, J., Williamson, I. G., Leydon, G., McDermott, L. M., Mullee, M., Stuart, B. L., & on behalf of the PIPS investigators (2013) · BMJ · doi:10.1136/bmj.f6041 · Cited by 101 · see citing works

Liver transplant associated with paracetamol overdose: results from the seven‐country SALT study

Gulmez, S. E., Larrey, D., Pageaux, G., Bernuau, J., Bissoli, F., Horsmans, Y., Thorburn, D., McCormick, P. A., Stricker, B., Toussi, M., et al. (2015) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.12635 · Cited by 99 · see citing works

Safety of Ibuprofen in Patients With COVID-19

Sodhi, M., & Etminan, M. (2020) · CHEST Journal · doi:10.1016/j.chest.2020.03.040 · Cited by 81 · see citing works

Covid-19: European drugs agency to review safety of ibuprofen

Day, M. J. (2020) · BMJ · doi:10.1136/bmj.m1168 · Cited by 75 · see citing works

Usage patterns of ‘over‐the‐counter’ vs. prescription‐strength nonsteroidal anti‐inflammatory drugs in F rance

Duong, M., Salvo, F., Pariente, A., Abouelfath, A., Lassalle, R., Droz‐Perroteau, C., Blin, P., & Moore, N. D. (2013) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.12239 · Cited by 71 · see citing works

Chloroquine for COVID-19 Infection

Moore, N. D. (2020) · Drug Safety · doi:10.1007/s40264-020-00933-4 · Cited by 58 · see citing works

Association between Angiotensin Blockade and Incidence of Influenza in the United Kingdom

Chung, S., Providencia, R. A., & Sofat, R. (2020) · New England Journal of Medicine · doi:10.1056/nejmc2005396 · Cited by 50 · see citing works

Hypertension and Renin–Angiotensin–Aldosterone System Inhibitors in Patients with Covid-19Preprint

Ip, A., Parikh, K., Parrillo, J. E., Mathura, S., Hansen, E., Sawczuk, I. S., & Goldberg, S. L. (2020) · medRxiv · doi:10.1101/2020.04.24.20077388 · Cited by 42 · see citing works

Usage patterns of paracetamol in France

Duong, M., Gülmez, S. E., Salvo, F., Abouelfath, A., Lassalle, R., Droz‐Perroteau, C., Blin, P., & Moore, N. D. (2016) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.12957 · Cited by 41 · see citing works

Identifying common pharmacotherapies associated with reduced COVID-19 morbidity using electronic health recordsPreprint

Castro, V. M., Ross, R., McBride, S. M. J., & Perlis, R. H. (2020) · medRxiv · doi:10.1101/2020.04.11.20061994 · Cited by 41 · see citing works

Considerations for pharmacoepidemiological analyses in the SARS‐CoV ‐2 pandemic

Pottegård, A., Kurz, X., Moore, N. D., Christiansen, C. F., & Klungel, O. H. (2020) · Pharmacoepidemiology and Drug Safety · doi:10.1002/pds.5029 · Cited by 41 · see citing works

COVID-19 and Avoiding Ibuprofen. How Good Is the Evidence?

Kutti Sridharan, G., Kotagiri, R., Chandiramani, V. H., Mohan, B. P., Vegunta, R., Vegunta, R., & Rokkam, V. R. P. (2020) · American Journal of Therapeutics · doi:10.1097/mjt.0000000000001196 · Cited by 34 · see citing works

Covid-19: ibuprofen can be used for symptoms, says UK agency, but reasons for change in advice are unclear

Torjesen, I. (2020) · BMJ · doi:10.1136/bmj.m1555 · Cited by 32 · see citing works

Nonsteroidal Antiinflammatory Drug Use and Clinical Outcomes of Community-acquired Pneumonia

Basille, D., Thomsen, R. W., Madsen, M., Duhaut, P., Andréjak, C., Jounieaux, V., & Sørensen, H. T. (2018) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201802-0229le · Cited by 27 · see citing works

COVID-19 pandemic and therapy with ibuprofen or renin-angiotensin system blockers: no need for interruptions or changes in ongoing chronic treatments

Zolk, O., Häfner, S., & Schmidt, C. Q. (2020) · Naunyn-Schmiedeberg s Archives of Pharmacology · doi:10.1007/s00210-020-01890-6 · Cited by 26 · see citing works

Should Patients Receiving ACE Inhibitors or Angiotensin Receptor Blockers be Switched to Other Antihypertensive Drugs to Prevent or Improve Prognosis of Novel Coronavirus Disease 2019 (COVID-19)?

the Italian Society of Pharmacology, Trifirò, G., Crisafulli, S., Andò, G., Racagni, G., & Drago, F. (2020) · Drug Safety · doi:10.1007/s40264-020-00935-2 · Cited by 25 · see citing works

Risk of hospital admission for liver injury in users of NSAIDs and nonoverdose paracetamol: Preliminary results from the EPIHAM study

Gülmez, S. E., Ünal, Ü. S., Lassalle, R., Chartier, A., Grolleau, A., & Moore, N. D. (2018) · Pharmacoepidemiology and Drug Safety · doi:10.1002/pds.4640 · Cited by 22 · see citing works

Previous Drug Exposure in Patients Hospitalised for Acute Liver Injury: A Case-Population Study in the French National Healthcare Data System

Moore, N. D., Duret, S., Grolleau, A., Lassalle, R., Barbet, V., Duong, M., Thurin, N. H., Droz‐Perroteau, C., & Gülmez, S. E. (2018) · Drug Safety · doi:10.1007/s40264-018-0752-1 · Cited by 15 · see citing works

Effects of Non-steroidal Anti-inflammatory Drugs (NSAIDs) and Gastroprotective NSAIDs on the Gastrointestinal Tract: A Narrative Review

Sohail, R., Mathew, M., Patel, K. K., Reddy, S. A., Haider, Z., Naria, M., Habib, A., Abdin, Z. U., Razzaq Chaudhry, W., & Akbar, A. (2023) · Cureus · doi:10.7759/cureus.37080 · Cited by 239 · see citing works

Paracetamol (acetaminophen): A familiar drug with an unexplained mechanism of action

Ayoub, S. S. (2021) · Temperature · doi:10.1080/23328940.2021.1886392 · Cited by 223 · see citing works

Early use of non-steroidal anti-inflammatory drugs in COVID-19 might reverse pathogenesis, prevent complications and improve clinical outcomes

Kelleni, M. T. (2020) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2020.110982 · Cited by 106 · see citing works

Nanomaterials for Photocatalytic Degradations of Analgesic, Mucolytic and Anti-Biotic/Viral/Inflammatory Drugs Widely Used in Controlling SARS-CoV-2

Ebrahimi, M., & Akhavan, O. (2022) · Catalysts · doi:10.3390/catal12060667 · Cited by 92 · see citing works

NSAIDs and COVID-19: A Systematic Review and Meta-analysis

Moore, N. D., Bosco‐Lévy, P., Thurin, N. H., Blin, P., & Droz‐Perroteau, C. (2021) · Drug Safety · doi:10.1007/s40264-021-01089-5 · Cited by 84 · see citing works

Paracetamol-Induced Glutathione Consumption: Is There a Link With Severe COVID-19 Illness?

Sestili, P., & Fimognari, C. (2020) · Frontiers in Pharmacology · doi:10.3389/fphar.2020.579944 · Cited by 58 · see citing works

COVID-19 in French patients with chronic inflammatory rheumatic diseases: Clinical features, risk factors and treatment adherence

Costantino, F., Bahier, L., Coronel, L., Leboime, A., Vidal, F., Bessalah, L., Bréban, M., & D’Agostino, M. A. (2020) · Joint Bone Spine · doi:10.1016/j.jbspin.2020.105095 · Cited by 52 · see citing works

An overview of SARS-COV-2 epidemiology, mutant variants, vaccines, and management strategies

Farooqi, T., Malik, J. A., Mulla, A. H., Hagbani, T. A., Almansour, K., Ubaid, M. A., Alghamdi, S., & Anwar, S. (2021) · Journal of Infection and Public Health · doi:10.1016/j.jiph.2021.08.014 · Cited by 48 · see citing works

Abnormal Liver Biochemistry Tests and Acute Liver Injury in COVID-19 Patients: Current Evidence and Potential Pathogenesis

McGrowder, D. A., Miller, F. G., Cross, M. A., Anderson-Jackson, L., Bryan, S., & Dilworth, L. (2021) · Diseases · doi:10.3390/diseases9030050 · Cited by 40 · see citing works

SARS-CoV-2 early infection signature identified potential key infection mechanisms and drug targets

Li, Y., Duche, A., Sayer, M. R., Roosan, D., Khalafalla, F. G., Ostrom, R. S., Totonchy, J. E., & Roosan, M. R. (2021) · BMC Genomics · doi:10.1186/s12864-021-07433-4 · Cited by 39 · see citing works

Interactions between ibuprofen, ACE2, renin‐angiotensin system, and spike protein in the lung. Implications for COVID‐19

Valenzuela, R., Pedrosa, M. A., Garrido‐Gil, P., Labandeira, C. M., Navarro, G., Franco, R., Rodriguez-Perez, A. I., & Labandeira-García, J. L. (2021) · Clinical and Translational Medicine · doi:10.1002/ctm2.371 · Cited by 34 · see citing works

Rationales and uncertainties for aspirin use in COVID-19: a narrative review

Ahmed, H. A. S., Merrell, E., Ismail, M., Joudeh, A. I., Riley, J. B., Shawkat, A., Habeb, H., Darling, E., Goweda, R. A., Shehata, M. H., et al. (2021) · Family Medicine and Community Health · doi:10.1136/fmch-2020-000741 · Cited by 33 · see citing works

Association Between Prescribed Ibuprofen and Severe COVID‐19 Infection: A Nationwide Register‐Based Cohort Study

Kragholm, K. H., Gerds, T. A., Fosbøl, E. L., Andersen, M. P., Phelps, M. D., Butt, J. H., Østergaard, L., Bang, C. N., Pallisgaard, J. L., Gislason, G., et al. (2020) · Clinical and Translational Science · doi:10.1111/cts.12904 · Cited by 33 · see citing works

Targeting cyclooxygenase enzyme for the adjuvant COVID ‐19 therapy

Prasher, P., Sharma, M., & Gunupuru, R. (2021) · Drug Development Research · doi:10.1002/ddr.21794 · Cited by 30 · see citing works

Paracetamol Is Associated with a Lower Risk of COVID-19 Infection and Decreased ACE2 Protein Expression: A Retrospective Analysis

Leal, N. S., Yu, Y., Chen, Y., Fedele, G., & Martins, L. M. (2021) · COVID · doi:10.3390/covid1010018 · Cited by 30 · see citing works

Survey-reported medication changes among older adults during the SARS-CoV-2 (COVID-19) pandemic

Brown, J. D., Vouri, S. M., & Manini, T. M. (2020) · Research in Social and Administrative Pharmacy · doi:10.1016/j.sapharm.2020.11.005 · Cited by 29 · see citing works

Challenges and Opportunities from Targeting Inflammatory Responses to SARS-CoV-2 Infection: A Narrative Review

Lariccia, V., Magi, S., Serfilippi, T., Toujani, M., Gratteri, S., & Amoroso, S. (2020) · Journal of Clinical Medicine · doi:10.3390/jcm9124021 · Cited by 28 · see citing works

Serious infectious events and ibuprofen administration in pediatrics: a narrative review in the era of COVID-19 pandemic

Quaglietta, L., Martinelli, M., & Staiano, A. (2021) · The Italian Journal of Pediatrics/Italian journal of pediatrics · doi:10.1186/s13052-021-00974-0 · Cited by 28 · see citing works

Utilization of drugs with reports on potential efficacy or harm on COVID ‐19 before, during, and after the first pandemic wave

Enners, S., Gradl, G., Kieble, M., Böhm, M., Laufs, U., & Schulz, M. (2021) · Pharmacoepidemiology and Drug Safety · doi:10.1002/pds.5324 · Cited by 26 · see citing works

Evaluation of SARS-CoV-2 entry, inflammation and new therapeutics in human lung tissue cells

Grau-Expósito, J., Perea, D., Suppi, M., Massana, N., Vergara, A., Soler, M. J., Trinité, B., Blanco, J., García‐Pérez, J., Alcamı́, J., et al. (2022) · PLoS Pathogens · doi:10.1371/journal.ppat.1010171 · Cited by 25 · see citing works

Wastewater surveillance of pharmaceuticals during the COVID-19 pandemic in Mexico City and the Mezquital Valley: A comprehensive environmental risk assessment

Durán–Álvarez, J. C., Prado, B., Zanella, R., Rodriguez, M. E., & Díaz, S. (2023) · The Science of The Total Environment · doi:10.1016/j.scitotenv.2023.165886 · Cited by 25 · see citing works

Comparative Anti-Inflammatory Effects of Salix Cortex Extracts and Acetylsalicylic Acid in SARS-CoV-2 Peptide and LPS-Activated Human In Vitro Systems

Le, N. P. K., Herz, C., Gomes, J. V. D., Förster, N., Antoniadou, K., Mittermeier-Kleßinger, V. K., Mewis, I., Dawid, C., Ulrichs, C., & Lamy, E. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22136766 · Cited by 27 · see citing works

Ibuprofen, other NSAIDs and COVID-19: a narrative review

Laughey, W. F., Lodhi, I., Pennick, G., Smart, L., Sanni, O., Sandhu, S., & Charlesworth, B. R. (2023) · Inflammopharmacology · doi:10.1007/s10787-023-01309-7 · Cited by 24 · see citing works

COVID-19: Current Developments and Further Opportunities in Drug Delivery and Therapeutics

Zafar, S., Arshad, M. S., Fatima, S., Ali, A. A. A., Zaman, A., Sayed, E., Chang, M., & Ahmad, Z. (2020) · Pharmaceutics · doi:10.3390/pharmaceutics12100945 · Cited by 23 · see citing works

Population-level interest in anti-rheumatic drugs in the COVID-19 era: insights from Google Trends

Kardeş, S., Kuzu, A. S., Pakhchanian, H. H., Raiker, R., & Karagülle, M. (2020) · Clinical Rheumatology · doi:10.1007/s10067-020-05490-w · Cited by 22 · see citing works

Management of COVID-19 in patients with seizures: Mechanisms of action of potential COVID-19 drug treatments and consideration for potential drug-drug interactions with anti-seizure medications

Jain, S., Potschka, H., Chandra, P. P., Tripathi, M., & Vohora, D. (2021) · Epilepsy Research · doi:10.1016/j.eplepsyres.2021.106675 · Cited by 22 · see citing works

Prostaglandins and non-steroidal anti-inflammatory drugs in Covid-19

Al-Kuraishy, H. M., Al-Gareeb, A. I., Al-Maiahy, T. J., Alexiou, A. T., Mukerjee, N., & Batiha, G. E. (2022) · Biotechnology and Genetic Engineering Reviews · doi:10.1080/02648725.2022.2122290 · Cited by 22 · see citing works

Ibuprofen, Flurbiprofen, Etoricoxib or Paracetamol Do Not Influence ACE2 Expression and Activity In Vitro or in Mice and Do Not Exacerbate In-Vitro SARS-CoV-2 Infection

de Bruin, N. M. W. J., Schneider, A., Reus, P., Talmon, S., Ciesek, S., Bojková, D., Cinatl, J. J., Lodhi, I., Charlesworth, B. R., Sinclair, S., et al. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23031049 · Cited by 20 · see citing works

Can Kratom (Mitragyna speciosa) Alleviate COVID-19 Pain? A Case Study

Metastasio, A., Prevete, E., Singh, D., Grundmann, O., Prozialeck, W. C., Veltri, C. A., Bersani, G., & Corazza, O. (2020) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2020.594816 · Cited by 20 · see citing works

Drugs Modulating Renin-Angiotensin System in COVID-19 Treatment

Labandeira-García, J. L., Labandeira, C. M., Valenzuela, R., Pedrosa, M. A., Quijano, A., & Rodriguez-Perez, A. I. (2022) · Biomedicines · doi:10.3390/biomedicines10020502 · Cited by 20 · see citing works

ACEIs, ARBs, ibuprofen originally linked to COVID-19: the other side of the mirror

Kelleni, M. T. (2020) · Inflammopharmacology · doi:10.1007/s10787-020-00755-x · Cited by 18 · see citing works

Drug-Based Therapeutic Strategies for COVID-19-Infected Patients and Their Challenges

Zarkesh, K., Entezar-Almahdi, E., Ghasemiyeh, P., Akbarian, M., Bahmani, M., Roudaki, S., Fazlinejad, R., Mohammadi‐Samani, S., Firouzabadi, N., Hosseini, M., et al. (2021) · Future Microbiology · doi:10.2217/fmb-2021-0116 · Cited by 18 · see citing works

The Abuse and Misuse of Over-the-Counter Medicines During COVID-19

Meslamani, A. Z. A., & Abdel‐Qader, D. H. (2023) · Hospital Pharmacy · doi:10.1177/00185787231158777 · Cited by 16 · see citing works

Indomethacin: Can It Counteract Bradykinin Effects in COVID-19 Patients?

Alkotaji, M. M., & Al-Zidan, R. N. (2021) · Current Pharmacology Reports · doi:10.1007/s40495-021-00257-6 · Cited by 16 · see citing works

A Review of Platelet-Activating Factor As a Potential Contributor to Morbidity and Mortality Associated with Severe COVID-19

Klein, M. A., Dao, V. X., & Khan, F. M. A. (2021) · Clinical and Applied Thrombosis/Hemostasis · doi:10.1177/10760296211051764 · Cited by 14 · see citing works

How can real‐world evidence aid decision making during the life cycle of nonprescription medicines?

Csőke, E., Landes, S., Francis, M. J., Ma, L., Pohlhaus, D. T., & Anquez‐Traxler, C. (2021) · Clinical and Translational Science · doi:10.1111/cts.13129 · Cited by 13 · see citing works

Home pharmacological therapy in early COVID‐19 to prevent hospitalization and reduce mortality: Time for a suitable proposal

Pandolfi, S., Chirumbolo, S., Ricevuti, G., Valdenassi, L., Bjørklund, G., Lysiuk, R., Doşa, M. D., Lenchyk, L. V., & Fazio, S. (2021) · Basic & Clinical Pharmacology & Toxicology · doi:10.1111/bcpt.13690 · Cited by 12 · see citing works

Can Non-steroidal Anti-inflammatory Drugs Affect the Interaction Between Receptor Binding Domain of SARS-COV-2 Spike and the Human ACE2 Receptor? A Computational Biophysical Study

González-Paz, L. A., Lossada, C. A., Fernández-Materán, F. V., Paz, J. L., Vera-Villalobos, J., & Alvarado, Y. J. (2020) · Frontiers in Physics · doi:10.3389/fphy.2020.587606 · Cited by 12 · see citing works

Bridging-BPs: a novel approach to predict potential drug–target interactions based on a bridging heterogeneous graph and BPs2vec

Li, G., Zhang, P., Sun, W., Ren, C., & Wang, L. (2021) · Briefings in Bioinformatics · doi:10.1093/bib/bbab557 · Cited by 10 · see citing works

COVID-19

(2005) · Radiopaedia.org · doi:10.53347/rid-73913 · Cited by 13 · see citing works

NSAIDs/Nitazoxanide/Azithromycin Immunomodulatory Protocol Used in Adult, Geriatric, Pediatric, Pregnant, and Immunocompromised COVID-19 Patients: A Real-World Experience

Kelleni, M. T. (2021) · Canadian Journal of Medicine · doi:10.33844/cjm.2021.60511 · Cited by 12 · see citing works

Drug-CoV: a drug-origin knowledge graph discovering drug repurposing targeting COVID-19

Li, S., Wong, K. W., Zhu, D., & Fung, C. C. (2023) · Knowledge and Information Systems · doi:10.1007/s10115-023-01923-5 · Cited by 9 · see citing works

Ibuprofen in the Management of Viral Infections: The Lesson of COVID‐19 for Its Use in a Clinical Setting

Marcianò, G., Muraca, L., Rania, V., & Gallelli, L. (2023) · The Journal of Clinical Pharmacology · doi:10.1002/jcph.2258 · Cited by 8 · see citing works

Partisanship and public opinion of COVID-19: does emphasizing Trump and his administration’s response to the pandemic affect public opinion about the coronavirus?

Spälti, A. K., Lyons, B. A., Mérola, V., Reifler, J., Stedtnitz, C., Stoeckel, F., & Szewach, P. (2021) · Journal of Elections Public Opinion and Parties · doi:10.1080/17457289.2021.1924749 · Cited by 8 · see citing works

Connecting the dots between inflammatory cascades of obesity and COVID-19 in light of mortal consequences—a review

Mal, P., Mukherjee, T., Upadhyay, A. K., Mohanty, S., & Pattnaik, A. K. (2022) · Environmental Science and Pollution Research · doi:10.1007/s11356-022-21461-x · Cited by 8 · see citing works

A review of cardiac involvement in COVID-19 infection

Afshar, Z. M., Babazadeh, A., Javanian, M., Ramezani, E., Shemshadi, R., & Ebrahimpour, S. (2020) · Cor et Vasa · doi:10.33678/cor.2020.102 · Cited by 6 · see citing works

Nonsteroidal Anti-Inflammatory Drugs in Viral Infections Disease, Specially COVID-19

Chamkouri, N., Absalan, F., Koolivand, Z., & Yousefi, M. (2023) · Advanced Biomedical Research · doi:10.4103/abr.abr_148_21 · Cited by 6 · see citing works

Coronavirus disease 2019: A comprehensive review on recent clinical updates and management tools for pharmacists

Deka, B., Dash, B., Newar, A., Ahmed, A., Bharali, A., Bordoloi, B., Rohman, T. A., Bingari, B., Bhattacharjee, B., Sadhukhan, P., et al. (2021) · Pharmaceutical and Biosciences Journal · doi:10.20510/pbj/9/i3/1363 · Cited by 5 · see citing works

Redesigning Ibuprofen for Improved Oral Delivery and Reduced Side Effects

Toth, S. H., Stoica, A. D., & Sevcencu, C. (2025) · Bioconjugate Chemistry · doi:10.1021/acs.bioconjchem.4c00558 · Cited by 4 · see citing works

A real-world disproportionality analysis of the FDA adverse event reporting system events for ibuprofen

Du, Y., Guo, Z., Xu, B., Yang, Y., Hu, M., Hu, Y., Yang, Y., Zhang, M., Wang, Z., Guo, X., et al. (2024) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2024.2348556 · Cited by 4 · see citing works

Platforms for Personalized Polytherapeutics Discovery in COVID-19

Hopkins, C. E., Onweni, C. L., Zambito, V., Fairweather, D., McCormick, K., Ebihara, H., Caulfield, T. R., Zhang, Y. S., & Freeman, W. D. (2021) · Journal of Molecular Biology · doi:10.1016/j.jmb.2021.166945 · Cited by 4 · see citing works

Vaccination and Therapeutics

Abdella, W. S., Selim, A. N., Diab, S., Qobeia, E., & Elgazzar, A. F. (2024) · Advances in experimental medicine and biology · doi:10.1007/978-3-031-61939-7_9 · Cited by 3 · see citing works

Diclofenac potassium/Nitazoxanide/Azithromycin Used in Adults, Children and Pregnant Patients: A Novel Potential Game Changer COVID-19 Protocol.Preprint

Kelleni, M. T. (2021) · doi:10.31219/osf.io/vmq3y · Cited by 3 · see citing works

Ibuprofen and COVID-19

Cervantes, J. (2021) · Clinical Infection and Immunity · doi:10.14740/cii122 · Cited by 2 · see citing works

Is there a place for anti-inflammatory therapy in COVID-19?

Yew, W. W., Chang, K. C., & Chan, D. P. C. (2020) · Journal of Thoracic Disease · doi:10.21037/jtd-20-2155 · Cited by 2 · see citing works

Antiinflammation Derived Suzuki-Coupled Fenbufens as COX-2 Inhibitors: Minilibrary Construction and Bioassay

Farn, S., Lai, Y.-B., Hua, K.-F., Chen, H.-P., Yu, T., Lo, S.-N., Shen, L.-H., Sheu, R.-J., & Yu, C. (2022) · Molecules · doi:10.3390/molecules27092850 · Cited by 2 · see citing works

No arguments for extra risk from ibuprofen in SARS-COV2 infection

Moore, N. D. (2020) · Therapies · doi:10.1016/j.therap.2020.07.006 · Cited by 2 · see citing works

Current knowledge about the etiopathogenesis and therapy options for COVID-19

Pešić, S., Jovanović, H., & Trajković, H. (2020) · Zdravstvena zastita · doi:10.5937/zdravzast49-28409 · Cited by 2 · see citing works

NSAIDs/Nitazoxanide/Azithromycin Immunomodulatory Protocol Used in Adults, Children and Pregnant COVID-19 Patients: An Egyptian Prospective Observational Study.Preprint

Kelleni, M. T. (2021) · doi:10.31219/osf.io/k8z5u · Cited by 2 · see citing works

Databases, DrugBank, and virtual screening platforms for therapeutic development

Middha, S. K., David, A., Haldar, S., Boro, H., Panda, P., Bajare, N., Milesh, L., Devaraj, V., & Usha, T. (2022) · Elsevier eBooks · doi:10.1016/b978-0-323-91172-6.00021-2 · Cited by 1 · see citing works

Characterization of Potential Intoxications with Medicines in a Regional Setting

Nascimento, T., Santos, T., Rato, F., & Sousa‐Coelho, A. L. D. (2023) · Pharmaceuticals · doi:10.3390/ph16020308 · Cited by 1 · see citing works

ХРОНІЧНЕ ОБСТРУКТИВНЕ ЗАХВОРЮВАННЯ ЛЕГЕНЬ ПОВ’ЯЗАНЕ З КОРОНАВІРУСНОЮ ХВОРОБОЮ 2019 (COVID-19)

Kuzminov, B. P., Мажак, К. Д., Ткач, О. А., & Рудницька, Н. Д. (2024) · Актуальні проблеми профілактичної медицини · doi:10.32782/2786-9067-2023-25-10 · Cited by 1 · see citing works

Are Healthcare Resource Utilization Patterns for Pain Management Specific to Post-Acute COVID-19 Syndrome? A Study of Survivors from the First French Pandemic Wave

Dziadzko, M. A., Belhassen, M., Ganse, E. H. V., Marant-Micallef, C., Martinez, V., & Aubrun, F. (2024) · Journal of Clinical Medicine · doi:10.3390/jcm13247680 · Cited by 1 · see citing works

Az ibuprofén helye a koronavírus-fertőzés kezelésében

Sütő, G. (2020) · Orvosi Hetilap · doi:10.1556/650.2020.32090 · Cited by 1 · see citing works

Exploration of interethnic variation in the ibuprofen metabolizing enzyme CYP2C9: a genetic-based cautionary guide for treatment of COVID-19 symptomsPreprint

Almarzooq, A. A. (2021) · medRxiv · doi:10.1101/2021.01.09.21249508 · Cited by 1 · see citing works

COVID-19 – Therapeutic controversies. The case of ibuprofen

Vari, C.-E., Groșan, A., Jîtcă, G., & Ősz, B.-E. (2020) · Romanian Journal of Pharmaceutical Practice · doi:10.37897/rjphp.2020.2.3

Diclofenac potassium/nitazoxanide/azithromycin novel COVID-19 protocol used in adults, children and pregnant patients: could it be the magic bullet?Preprint

Kelleni, M. T. (2020) · doi:10.22541/au.160797486.63735316/v1

Exploration of Interethnic Variation in the Ibuprofen Metabolizing Enzyme CYP2C9: A Cautionary Guide for Treatment of COVID-19 SymptomsPreprint

Almarzooq, A. A. (2021) · Research Square · doi:10.21203/rs.3.rs-156293/v1

COVID-19 chez les patients atteints de rhumatismes inflammatoires chroniques en France : caractéristiques cliniques, facteurs de risque et maintien thérapeutique

Costantino, F., Bahier, L., Coronel, L., Leboime, A., Vidal, F., Bessalah, L., Bréban, M., & D’Agostino, M. A. (2021) · Revue du Rhumatisme · doi:10.1016/j.rhum.2021.06.002

Relato de caso de adolescente suspeito de infecção pelo novo coronavírus

Martins, A. R., Cozac, A. B., Bruci, A. G. C., Prudente, A. L. R., Filho, R. A. S., Barros, P. G., & Silva, P. H. A. (2020) · Revista Master Ensino Pesquisa e Extensão · doi:10.47224/rm.v5i10.143

Data-Driven Patterns in Protective Effects of Ibuprofen and Ketorolac on Hospitalized Covid-19 PatientsPreprint

Lengerich, B. J., Caruana, R., & Aphinayanaphongs, Y. (2021) · medRxiv · doi:10.1101/2021.06.15.21258991

COVID-19: Should you be concerned about the use of ibuprofen?

Obońska, E., & Zapadka, M. (2021) · Farmacja Polska · doi:10.32383/farmpol/144257

Safe use of ibuprofen in COVID-19 in children

Borysovа, T. P. (2022) · CHILD`S HEALTH · doi:10.22141/2224-0551.17.1.2022.1495

COVID-19 Pandemisi Sırasında Anti Romatizmal İlaçlara Halkın İlgisi: Türkiye’deki Google Trends Analizi, Kesitsel Çalışma

Yücesoy, H., AYDIN, E. A., & Karaarslan, F. (2022) · Sakarya Medical Journal · doi:10.31832/smj.1035088

Evaluation of Jordan’s citizens’ awareness of the emerging Coronavirus (COVID-19) disease: A mixed analysis of the symptoms, transmission, and preventive measures

Almazari, I., Bdeir, R., & Basheer, H. A. (2022) · PLOS Global Public Health · doi:10.1371/journal.pgph.0001041

Effect of the Duration of NSAID Use on COVID-19

Kim, K., Yoon, S., Choi, J., & Lee, S. (2022) · Medicina · doi:10.3390/medicina58121713

Additional file 1 of SARS-CoV-2 early infection signature identified potential key infection mechanisms and drug targets

Li, Y., Duche, A., Sayer, M. R., Roosan, D., Khalafalla, F. G., Ostrom, R. S., Totonchy, J. E., & Roosan, M. R. (2021) · Figshare · doi:10.6084/m9.figshare.14059936

Feasibility of a Web-Based Visualization Tool for Estimating Ibuprofen Pharmacokinetic and Pharmacodynamic Profiles to Support Self-Medication

Pawestri, S. A., Okuba, K., & Ikeda, K. (2026) · Die Pharmazie · doi:10.31083/pharmazie55064

Does Ibuprofen worsen COVID-19 Disease?

Moore, N. D., Carleton, B., Blin, P., Bosco‐Lévy, P., & Droz‐Perroteau, C. (2021) · cIRcle (University of British Columbia) · doi:10.14288/1.0396342 · Cited by 1 · see citing works

Ibuprofen and COVID-19

Cervantes, J. (2021) · Clinical Infection and Immunity · doi:10.14740/cii122 · Cited by 2 · see citing works

Safety of Ibuprofen in Patients With COVID-19

Sodhi, M., & Etminan, M. (2020) · CHEST Journal · doi:10.1016/j.chest.2020.03.040 · Cited by 81 · see citing works

Is Ibuprofen Safe For COVID-19?

Khoury, Z., Galal, S., Skala-Wade, J., Uddin, N., Wolterink, T. D., & Russo, T. (2021) · Human Biology

COVID-19: Should you be concerned about the use of ibuprofen?

Obońska, E., & Zapadka, M. (2021) · Farmacja Polska · doi:10.32383/farmpol/144257